In order to substantiate the use of fluid-based biomarkers as surrogate endpoints in AD trials, understanding the relation of biomarker dynamics, e.g. if biomarker reduction below a certain threshold, within a critical time-window or between different groups (e.g. sex, APOE4 carriers) is required, will be key in the implementation as surrogate endpoints. Here, APOE is linked to Alzheimer disease.